Benzinga | Jan 27, 2022 06:52AM EST

European Commission Approves Merck's KEYTRUDA As Adjuvant Therapy For Certain Patients With Renal Cell Carcinoma Following Surgery

KEYTRUDA Is Now Approved as Monotherapy for Adults With RCC at Increased Risk of Recurrence Following Nephrectomy, or Following Nephrectomy and Resection of Metastatic Lesions

KEYTRUDA Is the First Immunotherapy Approved in Europe in the Adjuvant Setting for These Patients With RCC